Aurobindo's Clonazepam Purity Standards
Aurobindo Pharma, a major generic manufacturer, produces clonazepam tablets that meet United States Pharmacopeia (USP) standards for purity, as required for FDA approval of ANDAs. USP monograph for clonazepam specifies purity limits including ≤0.5% total impurities, with individual impurities capped at ≤0.2-0.3% depending on the type, and heavy metals ≤20 ppm.[1] Their product labeling and FDA filings confirm compliance with these specs, tested via HPLC for assay (97.0-103.0% of labeled amount) and degradation products.[2]
How Aurobindo Ensures Compliance
Aurobindo follows current Good Manufacturing Practices (cGMP) under FDA oversight, including validated analytical methods from USP <621> Chromatography. Certificates of Analysis (CoA) for their clonazepam lots report purity exceeding 99%, with impurity profiles below USP thresholds. They conduct stability testing per ICH Q1A guidelines, ensuring purity holds over shelf life (typically 24-36 months).[3]
FDA Inspections and Quality Issues
Aurobindo's clonazepam has faced FDA scrutiny. In 2019, their Unit VII facility (key for tablets) received a Form 483 with 10 observations on cleaning validation and lab controls, potentially impacting purity assurance. They resolved this via a 2020 consent decree, with no recent clonazepam-specific recalls for purity. However, a 2023 recall of other generics highlighted ongoing cGMP risks.[4][5]
Comparison to Brand Klonopin Purity
Roche's Klonopin (original clonazepam) also adheres to the same USP monograph. Generics like Aurobindo's must demonstrate bioequivalence and purity parity via FDA's therapeutic equivalence rating (AB for most clonazepam generics). No significant purity differences reported in post-market data.[6]
Checking Lot-Specific Purity
Patients or pharmacists can request CoA from Aurobindo via their customer service or NDC lookup (e.g., 65862-839 for 0.5mg tablets). USP-NF online provides the exact monograph.[1]
[1]: USP Clonazepam Monograph
[2]: FDA Orange Book - Aurobindo Clonazepam ANDA
[3]: Aurobindo Pharma Quality Report
[4]: FDA Warning Letter to Aurobindo 2019
[5]: FDA Recalls Database
[6]: FDA Therapeutic Equivalence Code Guide